Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the anticipated timing for reporting clinical trial results for tezampanel, the potential for tezampanel as a treatment for migraine and other pain indications and the potential of TorreyPines Therapeutics' product candidates to treat certain diseases and disorders. Such statements are subject to numerous factors, risks, and uncertainties that may cause actual events or results to differ materially from the combined company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support an NDA filing, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or whether the necessary financing to support its drug development programs will be available. Actual results may differ materi
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Resources, one of the world,s leading research and ... that the increased generic erosion of key drugs ... (Abbott/Sanofi-Aventis,s Depakote/Abbott,s Depakote ER, generics), combined with projected ... will cause a precipitous $2.3 billion decline in ...
... Aug. 25 Actelion Pharmaceuticals US, Inc., today ... (FDA) has approved the brand name VELETRI® for the ... available since April 2010 as Epoprostenol for Injection for ... (PAH) and PAH associated with the scleroderma spectrum of ...
Cached Medicine Technology:Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 3Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 4
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... 2013 The Rottenstein Law Group LLP, ... created the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol ... and those who are considering filing lawsuits. , ... cause severe liver damage, according to a 2009 report ... the “safety communication,” the FDA warned consumers against using ...
(Date:5/23/2013)... United States Vice President Dick Cheney served as the ... , In front of 1,500 guests yesterday at ... "I am delighted to be here to have the ... Year Award. I think it's a tremendous recognition; I ... company like this because there are obviously a great ...
(Date:5/23/2013)... Click here to read the full article: ... seeing their success develop through merger and acquisition ... to new research carried out by MaRS , the ... compiled its research into a series of articles and ... have shown the general trend that the success of ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Parker ... the rights of victims injured by defective medical devices ... Counsel Matthew J. McCauley has been appointed Co-Lead Counsel ... Mirena IUD Products Liability Litigation (Case 7:13-md-02434-CS). The Order, ... and Liaison Counsel are to submit their proposal for ...
Breaking Medicine News(10 mins):Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:U.S. District Court Appoints Parker Waichman LLP’s Matthew J. McCauley to Leadership Role in Mirena IUD Litigation 2
... , LOS ANGELES, Dec. 1 Gooooooaaaaaal! ... 2009/2010 growing season with a fresh starting lineup that expands ... an award-winning soccer player, coach and mom - will captain ... sidelines and online. Combined with league sponsorship expansion into Texas ...
... 2009 issue of the Journal of Thoracic Oncology ... metastatic lung cancer has improved over the last two decades ... an analysis of over 100,000 patients with stage IV non-small ... evaluate trends in survival between 1990 and 2005 to assess ...
... , LONDON, Dec. 1 ... devices market, particularly in the wireless assisted living devices segment. This ... this growth is rising awareness levels among an ageing population about ... elderly prefer to age at home - a trend supported by ...
... ... families prepare for and embrace caring for loved ones , ... Cincinnati, Ohio (PRWEB) December 2, 2009 -- Charles Puchta is ... , , ,“While we hope our loved ones live long, healthy and prosperous lives, the ...
... ... The American Meditation Institute (AMI) found that daily meditation, diaphragmatic breathing and yoga ... ... NY (PRWEB) December 1, 2009 –– A new retrospective, interview-based, case study found ...
... 1 "The patient will see you now." That is the ... of Minnesota,s 10,000 employees and family members today, becoming the first ... have access to Online Care Anywhere(SM). Online Care Anywhere allows patients ... onto a computer or picking up the phone. Blue Cross is ...
Cached Medicine News:Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 2Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 3Health News:Olympic Gold Medalist, World Cup Champion and Soccer Hall of Famer Joy Fawcett Sports A New Uniform as an Official Cuties(R) California Mandarin and Clementine Spokes-Mom 4Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 2Health News:Ageing Demographic Boosts Uptake of Wireless Patient Monitoring Devices Across Europe, Finds Frost & Sullivan 3Health News:Aging Expert's New Book Helps Boomers Address Challenges of Caregiving 2Health News:New American Meditation Institute Study Reports Wide-Ranging Health Benefits from Meditation and Yoga 2Health News:New American Meditation Institute Study Reports Wide-Ranging Health Benefits from Meditation and Yoga 3Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 2Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Medicine Products: